Pomerantz Law Firm Investigates Rafael Holdings Following Failed Phase 3 Clinical Trial
Pomerantz LLP has launched an investigation into Rafael Holdings, Inc. (NYSE: RFL) following a significant drop in its share price. The inquiry seeks to determine if the company or its executives engaged in securities fraud or unlawful business practices related to recent clinical trial disclosures. The investigation stems from a September 30, 2026, announcement regarding the Phase 3 TransportNPC™ study conducted by Rafael's subsidiary, Cyclo Therapeutics, LLC. The study evaluated Trappsol® Cyclo™ for Niemann-Pick Disease Type C but failed to achieve statistical significance on its primary endpoint. Following the news of the trial results, Rafael Holdings' stock price plummeted 34.98%, falling $0.71 per share to close at $1.32. The legal investigation aims to protect investors who may have suffered losses due to potential misrepresentations regarding the drug's efficacy and safety data.
Tickers: $RFL
Topics: class action lawsuit clinical trial failure securities fraud investigation stock price drop